This content is from: Premium Biopharma Funds Stumble in February But several funds may already be racking up big gains in March. By Stephen Taub March 16, 2023
This content is from: Premium Casdin Leads a Biopharma Surge Several funds that lost large amounts last year rebounded nicely in the first month of 2023. By Stephen Taub February 21, 2023
This content is from: Premium These Biopharma Funds Made a Comeback Last Year While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability. By Stephen Taub January 19, 2023
This content is from: Premium SEC Charges Perceptive Advisors The regulator has accused the life sciences firm headed by Joseph Edelman of engaging in violations related to its SPACs. By Stephen Taub September 06, 2022
This content is from: Premium Biopharma Funds Are Still Embracing VC The number of deals is down from last year, but most firms have still been fairly active in the private markets. By Stephen Taub December 21, 2022
This content is from: Premium The Prognosis Brightens for Biopharma Funds Soleus continues to lead the recovery in what had been one of the year’s most beaten-down sectors. By Stephen Taub December 14, 2022
